Highest-materiality recent filing
Arvinas, Pfizer, Rigel close VEPPANU license deal; $70M upfront received
HSR waiting period terminated June 11, 2026, making License Agreement effective.
Arvinas to out-license ARV-806 after completing Phase 1 dose escalation
Completed dose escalation enrollment for ARV-806 Phase 1 trial in KRAS G12D solid tumors.
Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel
FDA approved VEPPANU (vepdegestrant) for ESR1m, ER+/HER2- advanced breast cancer — first PROTAC therapy approved.
Arvinas and Pfizer out-license VEPPANU to Rigel for $85M upfront; potential $320M milestones
Rigel pays $70M upfront plus up to $15M upon completion of transition activities; split evenly with Pfizer.
Arvinas gets FDA approval for VEPPANU (vepdegestrant) in ESR1m breast cancer; first PROTAC approved
FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one prior endocrine therapy.
Arvinas reports Phase 1 ARV-102 shows >50% LRRK2 degradation in CSF in Parkinson's patients
ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF across all doses (20–80 mg) by day 14, maintained through day 28.
Arvinas reports Q4/FY2025 cash of $685.4M, appoints new CEO Randy Teel, PDUFA date June 2026
Cash and equivalents $685.4M at Dec 31, 2025 (vs $1,039.4M in 2024); runway into 2H 2028.
Arvinas appoints Randy Teel as CEO; John Houston resigns effective Feb 12, 2026
John Houston stepped down as President, CEO, and Chair on Feb 12; remains on board as director and consultant through March 1, 2027.
ARV-393 (3 mg/kg) + glofitamab achieved 81% TGI (concomitant) and 91% TGI (sequential) vs 38% and 36% single-agent.
Arvinas Q3 cash $787.6M; vepdegestrant NDA accepted PDUFA June 2026
Cash and securities $787.6M at Sept 30, 2025, down from $1,039.4M at Dec 31, 2024; cash runway into H2 2028.
Arvinas ARV-806 preclinical data: >90% KRAS G12D degradation for 7 days in xenograft models
ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type RAS.
Vepdegestrant showed reduced risk of deterioration vs fulvestrant in overall health status, pain severity, and functioning domains; statistically significant.
Arvinas presents positive Phase 1 data for ARV-102; biomarker modulation in CSF seen
ARV-102 well tolerated up to 200 mg single dose and 80 mg daily; no SAEs or discontinuations.
Arvinas and Pfizer to out-license vepdegestrant; cuts 15% workforce, authorizes $100M buyback
Plans to out-license vepdegestrant commercialization rights to a third party; PDUFA date June 5, 2026.
FDA accepts Arvinas NDA for vepdegestrant in ER+/HER2- advanced breast cancer; PDUFA June 2026
NDA based on Phase 3 VERITAC-2 trial showing statistically significant PFS improvement vs fulvestrant.
Arvinas Q2 2025: NDA for vepdegestrant; CEO to retire; cash $861M
Submitted NDA to FDA for vepdegestrant in ESR1m ER+/HER2- advanced breast cancer.
Arvinas CEO John Houston plans retirement; will remain Chairperson
John Houston, Ph.D., notified Arvinas of retirement as President and CEO on July 9, 2025.
Arvinas submits NDA to FDA for vepdegestrant in ER+/HER2- ESR1-mutated breast cancer
NDA supported by pivotal Phase 3 VERITAC-2 trial results presented at ASCO 2025 and published in NEJM.
Arvinas President of R&D Ian Taylor resigns, to serve as consultant for one year
Ian Taylor, Ph.D., President of Research and Development, resigned effective June 6, 2025.
Arvinas/Pfizer vepdegestrant VERITAC-2: PFS benefit in ESR1m patients; NDA in H2 2025
In ESR1m patients, vepdegestrant reduced progression/death risk by 43% (HR=0.57); median PFS 5.0 vs 2.1 months (p<0.001).
Arvinas cuts workforce 33%, reports positive VERITAC-2 data, removes two Phase 3 combo trials
Positive topline results from Phase 3 VERITAC-2 trial of vepdegestrant in 2L+ ER+/HER2- metastatic breast cancer; data accepted for ASCO 2025.
ARV-393 plus R-CHOP induced complete tumor regressions in all mice, outperforming single agents alone.
Arvinas Phase 1 data: ARV-102 achieves >50% central and >90% peripheral LRRK2 degradation
ARV-102 well tolerated in healthy volunteers; no serious adverse events in SAD (completed) or MAD (ongoing) cohorts.
Vepdegestrant met primary endpoint in ESR1m population: statistically significant PFS improvement, exceeded target HR of 0.60.
Arvinas reports Q4/FY2024 results; VERITAC-2 Phase 3 topline data expected in Q1 2025
Cash, cash equivalents and marketable securities $1,039.4M as of Dec 31, 2024; revenue $263.4M.
Arvinas updates Phase 3 vepdegestrant combo trials; VERITAC-2 topline data expected Q1 2025
Topline data for VERITAC-2 Phase 3 monotherapy trial of vepdegestrant expected in Q1 2025.
62.5% clinical benefit rate (10/16) and 26.7% ORR (4/15) in ER+/HER2- advanced breast cancer patients all previously treated with CDK4/6 inhibitor.
Arvinas delays VERITAC-2 Phase 3 top-line data to Q1 2025
Enrollment for vepdegestrant monotherapy trial in 2L breast cancer completed in Q4 2024.
Arvinas Q3 2024 revenue $102.4M; cash $1.12B; VERITAC-2 data on track 4Q24/1Q25
Q3 revenue $102.4M (vs $34.6M YoY) mainly from Novartis license $76.7M.
Arvinas terminates 163,784 sq ft New Haven lease for $41.5M cash termination fee
Lease termination effective Aug 15, 2024; covers floors 4-6 and part of 1st floor at 101 College Street, New Haven, CT.
Arvinas Q2 2024: $1.2B cash, $150M Novartis upfront, VERITAC-2 data 4Q24/1Q25
Cash, equivalents, and marketable securities $1.234B as of June 30, 2024; sufficient into 2027.
Arvinas amends Yale license, pays $14.95M upfront, $5M in 2025, eliminates minimum royalties
Upfront $14.95M to Yale for amended license and collaboration income from Novartis deal on ARV-766 and AR-V7.
Arvinas clears HSR for $150M upfront from Novartis; $1.01B milestones remain
HSR waiting period expired May 28, 2024; all closing conditions satisfied for the transaction.
Clinical benefit rate 63% across all doses; at RP3D 200 mg, CBR 67%; ORR 42% overall, 53% at 200 mg.
Arvinas Q1 cash $1.17B, licenses ARV-766 to Novartis for $150M upfront
Q1 2024 revenue $25.3M, down from $32.5M YoY; R&D expenses $84.3M vs $95.3M YoY.
Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones
Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.
Arvinas Q4/FY2023: revenue down 40% to $78.5M; CFO resigns, vepdegestrant Fast Track
FY2023 revenue $78.5M vs $131.4M prior; Q4 revenue negative $43.1M. R&D expense $379.7M. Cash $1.27B, sufficient into 2027.
Arvinas CFO Sean Cassidy steps down Feb 29; Randy Teel named interim CFO
Sean Cassidy will step down as CFO, Treasurer and principal financial officer effective Feb 29, 2024 to pursue another opportunity.
Arvinas gets FDA/EMA clearance for ARV-393 and ARV-102; Phase 1 trials planned H1 2024
FDA authorized IND for ARV-393, a PROTAC BCL6 degrader.
On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”).
On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development of Arvinas, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company and retire, effective June 6, 2025
and the appointment of Angela Cacace, Ph.D. as the Company’s chief scientific officer (“CSO”), a role previously held by Dr. Taylor.
On June 17, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Ian Taylor, Ph.D. as the Company’s president of research and development (“R&D”), a role previously held by John Houston, Ph.D.,
On March 18, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer, effective as of March 18, 2024.
On March 14, 2024, the Company notified Ron Peck, M.D., the Company’s previously serving chief medical officer, of Dr. Berkowitz’s pending appointment and the reassignment of the responsibilities of chief medical officer to Dr. Berkowitz effective as of March 18, 2024.
On February 15, 2024, Sean Cassidy indicated that he would step down as Chief Financial Officer, Treasurer and principal financial officer of Arvinas, Inc., a Delaware corporation (the “Company”), effective February 29, 2024, to pursue another professional opportunity.
On February 19, 2024, the Board of Directors of the Company appointed Randy Teel, Ph.D., the Company’s current Senior Vice President, Corporate and Business Development, to serve as the Company’s interim Chief Financial Officer, Treasurer and principal financial officer, effective February 29, 2024, while the Company undertakes a search to identify the Company’s next permanent Chief Financial Officer, Treasurer and principal financial officer.
On and effective December 15, 2022, upon recommendation from the Nominating and Corporate Governance Committee of the Board, the Board elected Everett Cunningham, age 55, as a director of the Company, effective immediately upon the resignation of Mr. Margus.
On December 14, 2022, Bradley Margus notified Arvinas, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”) and the Audit Committee of the Board, effective December 15, 2022.
On December 15, 2022, the Board appointed David Loomis, Vice President and Chief Accounting Officer of the Company, age 49, as principal accounting officer of the Company in lieu of Sean Cassidy, Chief Financial Officer and Treasurer of the Company.
On August 16, 2022, Liam Ratcliffe notified Arvinas, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective August 16, 2022.
Max materiality 1.00 · Median 0.68 · Most common event other_material